Susquehanna Fundamental Investments LLC Invests $476,000 in Cabaletta Bio, Inc. $CABA

Susquehanna Fundamental Investments LLC bought a new stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 152,964 shares of the company’s stock, valued at approximately $476,000. Susquehanna Fundamental Investments LLC owned about 0.09% of Cabaletta Bio as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of CABA. Kestra Advisory Services LLC bought a new stake in Cabaletta Bio in the first quarter worth $32,000. SummitTX Capital L.P. purchased a new position in Cabaletta Bio during the first quarter worth $34,000. Legal & General Group Plc bought a new position in Cabaletta Bio during the second quarter valued at $34,000. ANTIPODES PARTNERS Ltd bought a new position in Cabaletta Bio during the fourth quarter valued at $38,000. Finally, Clear Harbor Asset Management LLC purchased a new stake in shares of Cabaletta Bio in the fourth quarter valued at $43,000.

Cabaletta Bio Trading Up 8.2%

NASDAQ CABA opened at $3.57 on Thursday. The company’s 50-day moving average price is $2.93 and its 200-day moving average price is $3.11. The stock has a market cap of $605.26 million, a PE ratio of -2.27 and a beta of 3.27. Cabaletta Bio, Inc. has a 12 month low of $1.44 and a 12 month high of $4.23.

Cabaletta Bio (NASDAQ:CABA) last issued its earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. As a group, sell-side analysts forecast that Cabaletta Bio, Inc. will post -1.34 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on CABA shares. TD Cowen upgraded shares of Cabaletta Bio to a “strong-buy” rating in a report on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Cabaletta Bio from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Jefferies Financial Group restated a “buy” rating on shares of Cabaletta Bio in a research report on Wednesday, June 3rd. Finally, Wells Fargo & Company cut their target price on Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cabaletta Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.33.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.